European study finds that Gilead’s Covid-19 antiviral remdesivir shows no clinical benefit

Gilead’s remdesivir — or Veklury, as it’s marketed in the US — raked in around $2.8 billion last year as the only FDA-approved antiviral to treat Covid-19. But new data from a European study suggest the drug, which has been given to about half of hospitalized Covid patients in the…

...

Click to view original post